$INTI
Inhibitor Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000119312522284610 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $423.6K $69.99K $66.25K
YoY Change 1377.13% 5.65% -75.49%
% of Gross Profit
Research & Development $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $423.6K $69.99K $66.25K
YoY Change 1373.02% 5.64% -78.12%
Operating Profit -$69.99K -$66.25K
YoY Change 5.64% -78.12%
Interest Expense -$3.360K -$7.710K -$4.800K
YoY Change -30.0% 60.63% -48100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $12.42M -$77.69K -$71.05K
YoY Change -37094.96% 9.35% -76.53%
Income Tax $55.11K
% Of Pretax Income 0.44%
Net Earnings $12.32M -$77.69K -$71.05K
YoY Change -36813.2% 9.35% -76.53%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.04 $0.00 -$188.60
COMMON SHARES
Basic Shares Outstanding 376.9M 376.9M 376.7M
Diluted Shares Outstanding 376.9M 376.7M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.95M $53.06K $53.29K
YoY Change 38918.02% -0.43% 45.16%
Cash & Equivalents $12.00M $53.06K $53.29K
Short-Term Investments
Other Short-Term Assets $23.90K $10.06K $36.79K
YoY Change -15.13% -72.66% 4.25%
Inventory
Prepaid Expenses $23.90K $10.06K
Receivables
Other Receivables
Total Short-Term Assets $11.98M $63.12K $90.08K
YoY Change 20271.4% -29.93% 25.11%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.440K
YoY Change -92.31%
Total Long-Term Assets $0.00 $0.00 $2.440K
YoY Change -100.0% -92.31%
TOTAL ASSETS
Total Short-Term Assets $11.98M $63.12K $90.08K
Total Long-Term Assets $0.00 $0.00 $2.440K
Total Assets $11.98M $63.12K $92.52K
YoY Change 20271.4% -31.78% -10.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $145.2K $326.5K $304.8K
YoY Change -48.13% 7.1% 21.19%
Accrued Expenses $122.6K $34.85K $10.16K
YoY Change 719.11% 243.01%
Deferred Revenue
YoY Change
Short-Term Debt $411.0K $411.0K $192.5K
YoY Change 77.92% 113.51% 732.97%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $678.8K $1.088M $590.9K
YoY Change -0.12% 84.08% 28.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $38.50K
YoY Change -100.0% 108.22%
Other Long-Term Liabilities $3.000M $3.000M $3.000M
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Liabilities $3.000M $3.000M $3.039M
YoY Change 0.0% -1.27% 0.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $678.8K $1.088M $590.9K
Total Long-Term Liabilities $3.000M $3.000M $3.039M
Total Liabilities $3.679M $4.088M $3.629M
YoY Change -0.02% 12.63% 4.38%
SHAREHOLDERS EQUITY
Retained Earnings -$45.75M -$58.07M
YoY Change -20.66%
Common Stock $54.05M $50.09M
YoY Change 7.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.296M -$4.025M -$3.537M
YoY Change
Total Liabilities & Shareholders Equity $11.98M $63.12K $92.52K
YoY Change 20271.4% -31.78% -10.81%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income $12.32M -$77.69K -$71.05K
YoY Change -36813.2% 9.35% -76.53%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $11.90M -$51.89K -$40.43K
YoY Change -52607.37% 28.35% -59.82%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 80.00K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities 11.90M -51.89K -40.43K
Cash From Investing Activities
Cash From Financing Activities 0.000 80.00K 0.000
Net Change In Cash 11.90M 28.11K -40.43K
YoY Change -52607.37% -169.53% -59.82%
FREE CASH FLOW
Cash From Operating Activities $11.90M -$51.89K -$40.43K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-13467
dei Entity Registrant Name
EntityRegistrantName
Inhibitor Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
30-0793665
dei Entity Address Address Line1
EntityAddressAddressLine1
449 South 12th Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Unit 1705
dei Entity Address City Or Town
EntityAddressCityOrTown
Tampa
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33602
dei City Area Code
CityAreaCode
888
dei Local Phone Number
LocalPhoneNumber
841-6811
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
376858323
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53058
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30626
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10059
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
28158
CY2022Q3 us-gaap Assets Current
AssetsCurrent
63117
CY2021Q4 us-gaap Assets Current
AssetsCurrent
58784
CY2022Q3 us-gaap Assets
Assets
63117
CY2021Q4 us-gaap Assets
Assets
58784
us-gaap Revenues
Revenues
0
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
326464
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
279842
CY2022Q3 us-gaap Dividends Payable Current
DividendsPayableCurrent
250413
CY2021Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
100823
CY2022Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
411000
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
231000
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
34845
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
14965
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
65000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
53000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1087722
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
679630
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2022Q3 us-gaap Liabilities
Liabilities
4087722
CY2021Q4 us-gaap Liabilities
Liabilities
3679630
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
376858323
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
376858323
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
376858323
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
376858323
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
37686
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
37686
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
50051711
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
50051711
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58074868
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57671109
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4024605
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-3620846
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
63117
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58784
CY2022Q3 us-gaap Revenues
Revenues
0
CY2021Q3 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6150
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4830
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
69987
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
66248
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
228141
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
291806
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
69987
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
66248
us-gaap Operating Expenses
OperatingExpenses
234291
us-gaap Operating Expenses
OperatingExpenses
296636
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-69987
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-66248
us-gaap Operating Income Loss
OperatingIncomeLoss
-234291
us-gaap Operating Income Loss
OperatingIncomeLoss
-296636
CY2022Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
7705
CY2021Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
4803
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
19878
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
10035
CY2022Q3 us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
0
CY2021Q3 us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
0
us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
0
us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
41600
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-77692
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-71051
us-gaap Net Income Loss
NetIncomeLoss
-254169
us-gaap Net Income Loss
NetIncomeLoss
-265071
CY2022Q3 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
50411
CY2021Q3 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
50412
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
149590
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
149590
CY2022Q3 inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-128103
CY2021Q3 inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-121463
inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-403759
inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-414661
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
376858323
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
376858323
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
376708894
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
376708894
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
376858323
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
376858323
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
376042025
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
376042025
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-3620846
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49315
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-98910
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-3769071
CY2022Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49864
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-77567
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-3896502
CY2022Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
50411
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-77692
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4024605
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3360203
CY2021Q1 us-gaap Stock Issued During Period Value Dividend Reinvestment Plan
StockIssuedDuringPeriodValueDividendReinvestmentPlan
100822
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
37990
CY2021Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49315
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-127838
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-3398544
CY2021Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49863
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-66182
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-3514589
CY2021Q3 us-gaap Stock Issued During Period Value Dividend Reinvestment Plan
StockIssuedDuringPeriodValueDividendReinvestmentPlan
99178
CY2021Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
50412
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-71051
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-3536874
us-gaap Profit Loss
ProfitLoss
-254169
us-gaap Profit Loss
ProfitLoss
-265071
us-gaap Share Based Compensation
ShareBasedCompensation
0
us-gaap Share Based Compensation
ShareBasedCompensation
37990
us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
0
us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
41600
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-18099
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17469
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
78502
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
53440
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-157568
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-197772
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
180000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
176000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
180000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
176000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22432
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21772
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30626
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75059
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53058
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53287
us-gaap Stock Issued1
StockIssued1
0
us-gaap Stock Issued1
StockIssued1
200000
inti Accrued But Unpaid Dividends
AccruedButUnpaidDividends
250413
inti Accrued But Unpaid Dividends
AccruedButUnpaidDividends
50412
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
inti Royalty Rate On Net Sales
RoyaltyRateOnNetSales
0.09
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53058
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. </div></div>
CY2022Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
231000
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
281000
CY2022Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
411000

Files In Submission

Name View Source Status
0001193125-22-284610-index-headers.html Edgar Link pending
0001193125-22-284610-index.html Edgar Link pending
0001193125-22-284610.txt Edgar Link pending
0001193125-22-284610-xbrl.zip Edgar Link pending
d346720d10q.htm Edgar Link pending
d346720d10q_htm.xml Edgar Link completed
d346720dex311.htm Edgar Link pending
d346720dex312.htm Edgar Link pending
d346720dex321.htm Edgar Link pending
d346720dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
inti-20220930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
inti-20220930_cal.xml Edgar Link unprocessable
inti-20220930_def.xml Edgar Link unprocessable
inti-20220930_pre.xml Edgar Link unprocessable
inti-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable